Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ricinus communis agglutinin (RCA), specifically the RCA120 form, is a galactose-binding lectin isolated from the seeds of the castor bean plant (Ricinus communis) [UniProt, PubChem]. It is a member of the type II ribosome-inactivating protein (RIP) family and is structurally related to the highly toxic protein ricin, though RCA120 exists as a 120 kDa tetramer composed of two A-chains and two B-chains [NCBI, Wikipedia]. The B-chains are responsible for high-affinity binding to terminal galactose or N-acetylgalactosamine residues on the surface of eukaryotic cells, facilitating internalization via endocytosis [PubMed]. Once inside the cell, the A-chain functions as an N-glycosidase that depurinates the 28S ribosomal RNA, which irreversibly halts protein synthesis and induces cell death [UniProt]. While RCA is significantly less toxic than ricin due to its larger size and less efficient cytosolic translocation, it remains highly lethal and is used in laboratories to study cell-surface carbohydrates and neuronal pathways [NCBI]. In clinical research, it has been explored as a potential component of immunotoxins for targeted cancer therapy, where it is conjugated to antibodies to specifically eliminate tumor cells [PubMed].
Binds to terminal galactose residues on cell surfaces via B-chains and inhibits protein synthesis by depurinating 28S ribosomal RNA via A-chains.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ricinus communis agglutinin (RCA120).